KDIGO
KDIGO
  • 203
  • 410 766
APOL1 Controversies Conference Plenary Presentation: APOL1 Diagnostics and Therapeutics
This is a recording of the plenary presentation, "APOL1 Diagnostics and Therapeutics," by Dr. Kirk Campbell (United States) from the KDIGO Controversies Conference on APOL1 Kidney Disease.
Dr. Akinlolu Ojo (United States) and Dr. Ifeoma Ulasi (Nigeria) co-chaired this conference in Accra, Ghana, in April 2024. The conference brought together key thought leaders and relevant stakeholders, including patients, caregivers, experts in nephrology, and other related disciplines (genetics, epidemiology, ethics, immunology, etc.) to comprehensively review the literature and address clinical issues.
For more information and related resources, please visit: kdigo.org/conferences/controversies-conference-on-apol1/
You can watch all plenary presentations on the APOL1 Controversies Conference playlist: kdigo.co/APOL1-2024-Conference-Plenaries
Переглядів: 190

Відео

APOL1 Controversies Conference Plenary: Patient & Caregiver Panel Discussion
Переглядів 5414 днів тому
This is a recording of the Patient & Caregiver Panel Discussion from the KDIGO Controversies Conference on APOL1 Kidney Disease. The discussion took place during the conference plenary presentations. Dr. Akinlolu Ojo (United States) and Dr. Ifeoma Ulasi (Nigeria) co-chaired this conference in Accra, Ghana, in April 2024. The conference brought together key thought leaders and relevant stakehold...
APOL1 Controversies Conference Plenary: Ethics of Genetic Testing
Переглядів 6914 днів тому
This is a recording of the plenary presentation, "Ethics of Genetic Testing," by Dr. Rulan Parekh (Canada) from the KDIGO Controversies Conference on APOL1 Kidney Disease. Dr. Akinlolu Ojo (United States) and Dr. Ifeoma Ulasi (Nigeria) co-chaired this conference in Accra, Ghana, in April 2024. The conference brought together key thought leaders and relevant stakeholders, including patients, car...
APOL1 Controversies Conference Plenary: Epidemiology of APOL1 Kidney Disease
Переглядів 14514 днів тому
This is a recording of the plenary presentation, "Epidemiology of APOL1 Kidney Disease," by Dr. Sarala Naicker (South Africa) from the KDIGO Controversies Conference on APOL1 Kidney Disease. Dr. Akinlolu Ojo (United States) and Dr. Ifeoma Ulasi (Nigeria) co-chaired this conference in Accra, Ghana, in April 2024. The conference brought together key thought leaders and relevant stakeholders, incl...
APOL1 Controversies Conference Plenary: APOL1 Pathophysiology
Переглядів 19314 днів тому
This is a recording of the plenary presentation "APOL1 Pathophysiology" by Dr. David Friedman (United States) from the KDIGO Controversies Conference on APOL1 Kidney Disease. Dr. Akinlolu Ojo (United States) and Dr. Ifeoma Ulasi (Nigeria) co-chaired this conference in Accra, Ghana, in April 2024. The conference brought together key thought leaders and relevant stakeholders, including patients, ...
Personalizing Our Approach: A Focus on Managing the Non-diabetic Patient in CKD
Переглядів 60521 день тому
This is the fifth webinar in a five-part series on the holistic approach to evaluating and managing chronic kidney disease (CKD) based on the KDIGO 2024 CKD Guideline. In this webinar, KDIGO CKD Guideline Work Group Members Rasheeda Hall, MD (United States) and William Herrington, MD (United Kingdom) guide attendees through an interactive case study to show the step-wise approach to managing pa...
KDIGO 2024 Guideline on Lupus Nephritis (LN): A Roundtable Discussion
Переглядів 1,7 тис.Місяць тому
This is a recording of the session "KDIGO 2024 Guideline on Lupus Nephritis (LN): A Roundtable Discussion" from the 2024 ERA Congress in Stockholm, Sweden. The session was co-chaired by KDIGO LN Guideline Co-Chair Brad Rovin, MD (United States) and LN Guideline Work Group Member Vladimir Tesar, MD (Czechia), with presentations by LN Guideline Work Group Members Juan Manuel Mejía Vilet, MD (Mexi...
KDIGO Scientific Symposium on the Impact of Viral Infection and the Role of Vaccines in Kidney Care
Переглядів 522Місяць тому
This is a recording of the KDIGO scientific symposium, "The Impact of Viral Infections in Patients with Renal Diseases and the Role of Vaccination in Kidney Care," which was held at the 61st ERA Congress in Stockholm, Sweden, in May 2024. The symposium was chaired by Steven Chadban, MD (Australia), with speakers Uyen Huynh-Do, MD (China), Michel Jadoul, MD (Belgium), and Deepali Kumar, MD (Cana...
KDIGO Heart Failure & Kidney Disease Conference Plenary: Patient Panel
Переглядів 254Місяць тому
This is a recording of the patient panel plenary presentation from the KDIGO 2024 Controversies Conference on Kidney Disease and Heart Failure: Recent Advances and Current Challenges. The conference was held in Vancouver, Canada, in March 2024. Dr. Nisha Bansal (University of Washington, United States) and Dr. Carolyn Lam (National Heart Centre Singapore and Duke-National University of Singapor...
KDIGO Heart Failure & CKD Conference Plenary: Prediction of Heart Failure in Patients with CKD
Переглядів 346Місяць тому
This is a recording of "Prediction of Heart Failure in Patients with CKD," a plenary presentation by Dr. Josef Coresh (Optimal Aging Institute and NYU Grossman School of Medicine, United States) from the KDIGO 2024 Controversies Conference on Kidney Disease and Heart Failure: Recent Advances and Current Challenges. The conference was held in Vancouver, Canada, in March 2024. Dr. Nisha Bansal (U...
KDIGO Heart Failure & Kidney Disease Conference Plenary: Interdisciplinary Care Models
Переглядів 179Місяць тому
This is a recording of "Interdisciplinary Care Models: Implementation Strategies to Address Global Unmet Needs," a plenary presentation by Dr. Elke Eaton (University Hospitals Cleveland, United States), Dr. Debasish Banerjee (St George's University Hospitals NHS Foundation Trust, United Kingdom), and Dr. Lisa Anderson (St George's Hospital London, United Kingdom) from the KDIGO 2024 Controversi...
KDIGO Heart Failure & Kidney Disease Conference Plenary: A New Era of GDMT
Переглядів 978Місяць тому
This is a recording of "A New Era of GDMT: Are We Witnessing a Convergence of GDMT for Heart Failure and CKD?," a plenary presentation by Dr. Brendon Neuen (Royal North Shore Hospital and The George Institute for Global Health, Australia) from the KDIGO 2024 Controversies Conference on Kidney Disease and Heart Failure: Recent Advances and Current Challenges. The conference was held in Vancouver...
KDIGO Heart Failure & Kidney Disease Conference Plenary: New AHA CKM Staging
Переглядів 375Місяць тому
This is a recording of "New AHA Cardiovascular-Kidney-Metabolic (CKM) Staging Solves All Our Staging Problems and Should Be Applied Universally: A Cardiology and Nephrology Perspective," a plenary session presentation by Dr. Robert Mentz (Duke University, United States) and Dr. Adeera Levin (University of British Columbia St Paul's Hospital, Canada) from the KDIGO 2024 Controversies Conference ...
KDIGO 2024 Guideline for Chronic Kidney Disease: Key Messages for Primary Care Physicians
Переглядів 822Місяць тому
In this video, Dr. Xavier Cos (Spain) shares crucial insights and key messages for primary care physicians about the timely diagnosis of chronic kidney disease (CKD) and prompt initiation of its treatment. Specifically, Dr. Cos highlights the importance of early detection of CKD and the means for its proper staging and risk stratification. Most importantly, Dr. Cos details the medical approache...
KDIGO 2024 ANCA Vasculitis Guideline: Reading Between the Lines
Переглядів 1,5 тис.Місяць тому
In this webinar, KDIGO 2024 ANCA Vasculitis Guideline Co-Chair Brad Rovin, MD (United States), and Geetha Duvuru, MD (United States) review the latest KDIGO guidance using case-based studies, including a discussion on indications for plasma exchange and avacopan, to showcase challenging patient scenarios and illustrate the optimal application of guideline recommendations and practice points. To...
61st ERA Congress Highlights on Complement-Mediated Kidney Disease with Marina Vivarelli
Переглядів 454Місяць тому
61st ERA Congress Highlights on Complement-Mediated Kidney Disease with Marina Vivarelli
61st ERA Congress Highlights on IgA Nephropathy with Jonathan Barratt
Переглядів 633Місяць тому
61st ERA Congress Highlights on IgA Nephropathy with Jonathan Barratt
A Contemporary Approach to Treatment of Anemia for Dialysis Patients: A KDIGO Perspective
Переглядів 8812 місяці тому
A Contemporary Approach to Treatment of Anemia for Dialysis Patients: A KDIGO Perspective
Expert Roundtable Discussion on Dialysis-Related Amyloidosis (DRA)
Переглядів 3382 місяці тому
Expert Roundtable Discussion on Dialysis-Related Amyloidosis (DRA)
Dialysis-Related Amyloidosis (DRA): We Still Have a Long Way to Go
Переглядів 2442 місяці тому
Dialysis-Related Amyloidosis (DRA): We Still Have a Long Way to Go
Dialysis-Related Amyloidosis: A Perspective from the US
Переглядів 3012 місяці тому
Dialysis-Related Amyloidosis: A Perspective from the US
Pathophysiology of Dialysis-Related Amyloidosis: B2-Microglobulin-Related Amyloid Fibril Formation
Переглядів 3602 місяці тому
Pathophysiology of Dialysis-Related Amyloidosis: B2-Microglobulin-Related Amyloid Fibril Formation
KDIGO 2024 Guideline on ANCA-Associated Vasculitis: Update on Current Management and Treatment
Переглядів 3 тис.2 місяці тому
KDIGO 2024 Guideline on ANCA-Associated Vasculitis: Update on Current Management and Treatment
Part 2: An Expert Approach to Cardiorenal Protection in CKD
Переглядів 7102 місяці тому
Part 2: An Expert Approach to Cardiorenal Protection in CKD
Part 1: An Expert Approach to Cardiorenal Protection in CKD
Переглядів 1,1 тис.2 місяці тому
Part 1: An Expert Approach to Cardiorenal Protection in CKD
Optimising RAASi Management in Cardiorenal Patients
Переглядів 6582 місяці тому
Optimising RAASi Management in Cardiorenal Patients
Personalizing Our Approach: A Focus on Targeting Diabetes with Concomitant CKD
Переглядів 6222 місяці тому
Personalizing Our Approach: A Focus on Targeting Diabetes with Concomitant CKD
Personalizing Our Approach: A Focus on the Diagnosis and Prognosis of CKD
Переглядів 6672 місяці тому
Personalizing Our Approach: A Focus on the Diagnosis and Prognosis of CKD
Leaving No Stone Unturned: Optimizing Management for Patients with CKD
Переглядів 1,8 тис.3 місяці тому
Leaving No Stone Unturned: Optimizing Management for Patients with CKD
Tailored Care: A Push Towards Personalization in the Diagnosis and Prognosis of CKD
Переглядів 1,5 тис.3 місяці тому
Tailored Care: A Push Towards Personalization in the Diagnosis and Prognosis of CKD

КОМЕНТАРІ

  • @grandmajane2593
    @grandmajane2593 2 години тому

    Nothing new here to report, folks.

  • @ShimmyMD
    @ShimmyMD 16 годин тому

    What an excellent video /summary. Great job 👏🏼

  • @ShimmyMD
    @ShimmyMD 4 дні тому

    Dr Tangri - one comment (constructive criticism if I may) I looked at the guidelines and they make a note that nuclear imaging is not as reliable as something like iohexol. Maybe I’m missing something?

  • @ShimmyMD
    @ShimmyMD 4 дні тому

    Dr Tangri is an excellent teacher. I’m glad you were part of this panel.

  • @ShimmyMD
    @ShimmyMD 4 дні тому

    Amazing presentation. I really like the panel style. Keeps it interactive.

  • @DoctorsTalking-hj2qv
    @DoctorsTalking-hj2qv 7 днів тому

    how to pronounce this word?

  • @gerrraw
    @gerrraw 14 днів тому

    Thanks

  • @RafaelLMello01
    @RafaelLMello01 20 днів тому

    crie um projeto react com java script, contendo os seguintes itens: crie um componente react que renderize um botão com o texto: “Clique aqui” crie um componente react que renderize uma lista de números. a Lista deve ser atualizada quando o usuário clicar no botão na questão anterior crie um componente react que renderize um formulário de login. O formulário deve ter os campos e-mail e senha. crie um roteamento que inclua pelo menos duas páginas diferentes sendo uma delas: um texto informativo com alguns parágrafos sobre a importância dos softwares nos dias atuais e a outra um texto informativo sobre negócios. integre o framework bootstrap com a aplicação react. todos os elementos devem ter o seu estilo modificado pelo framework implemente uma rota de navegação autenticada em react. ou seja, crie um fluxo em que o usuário só pode acessar determinada rota se estiver autenticado. as credenciais do usuário obtidas pelo formulário de login podem ser verificadas diretamente com strings pré-definidas no código como email = “admin” e senha igual a “1234” para autenticar o usuário. as interfaces devem seguir heurísticas de ux design e ui design para ficarem melhores

  • @claudio5995
    @claudio5995 22 дні тому

    Hello. Why CKD G1 is >90 and have no an upper limit? When there is hyperfiltration?

  • @Koronajewell
    @Koronajewell Місяць тому

    I'm a dialysis patient in the US. I take fish oils every morning before dialysis instead of using heparin as a blood thinner. The one day I forgot to take my fish oil, the dialysis machine clotted up. Fish oil does work for me.

  • @Dr_Sri_Harsha_Guthikonda
    @Dr_Sri_Harsha_Guthikonda Місяць тому

    Certainly! Based on the video transcript, here are the chapters for the video: **Chapter 1: Introduction to IGA Nephropathy and FSGS Webinar** [00:00:05][^1^][1] - Greetings and welcome - Overview of the webinar series - Introduction of speakers **Chapter 2: Diagnosing IGA Nephropathy** [00:01:17][^2^][2] - Pathology basis for diagnosis - Characteristics of IGA Nephropathy - Differential diagnosis and distinguishing factors **Chapter 3: Pathophysiology and Clinical Aspects of IGA Nephropathy** [00:13:22][^3^][3] - Historical perspective of IGA Nephropathy - Clinical trials and targeting pathways - Importance of blood pressure control and lifestyle modifications **Chapter 4: Biopsy Predictors and Stratification** [00:07:24][^4^][4] - The role of renal biopsy in diagnosis and prognosis - International consensus on classification - The Oxford approach to classification **Chapter 5: Clinical Implications of Biopsy Findings** [00:42:42][^5^][5] - The significance of crescents in IGA Nephropathy - The importance of clinical context in treatment decisions **Chapter 6: Lifestyle Modifications and Patient Management** [00:32:23][^6^][6] - Supportive therapy approaches - The impact of diet, obesity, and smoking on IGA Nephropathy - Recommendations for physical activity **Chapter 7: Conclusion and Q&A Session** [00:47:13][^7^][7] - Summary of key points from the webinar - Audience questions and expert responses - Closing remarks and future webinars These chapters provide a structured overview of the video's content, making it easier to navigate through the different topics discussed. If you need more detailed information or specific time stamps for each chapter, feel free to ask!

  • @bondardmytro2783
    @bondardmytro2783 Місяць тому

    What is MRST classification?

  • @darkeio
    @darkeio Місяць тому

    thank you so much for your lecture

  • @kevinwellwrought2024
    @kevinwellwrought2024 Місяць тому

    My protein 24 hour is over 1000. As long as I take cortisol it stays the same but whenever I stop it startd going over 1000. This proves that cortisols are just like painkillers and do not treat IGA and second IGA has no treatment and medical sciences are all defeated by it

  • @a.m.hherez3460
    @a.m.hherez3460 Місяць тому

    Whats GDMT

    • @vietleuc913
      @vietleuc913 Місяць тому

      Guideline-Directed Medical Therapy

  • @kleptocracyrulez763
    @kleptocracyrulez763 Місяць тому

    Wonderful discussion...

  • @dipeesingh9242
    @dipeesingh9242 Місяць тому

    Does that mean weight lifting causes blood pressure to be raised to a level that it damages kidney irreversibly everytime? Very counter intuitive!!!

  • @drvishwaprakashtiwari1217
    @drvishwaprakashtiwari1217 2 місяці тому

    Any suggestion regarding duration of maintance

  • @hamadaadl5637
    @hamadaadl5637 2 місяці тому

    Thanks

  • @hamadaadl5637
    @hamadaadl5637 2 місяці тому

    Thank you

  • @badrulmunir8042
    @badrulmunir8042 3 місяці тому

    Thank you for sharing

  • @conjeevaramkesavan5467
    @conjeevaramkesavan5467 3 місяці тому

    Excellent thoughts Several Major issues Lack of concern for humanity and no forethought Total inertia even in application of measures Big pharma driving business for pharmacotherapy using human Guinea pigs paying medical professionals Ruthless greed making cost of newer medicines absolutely unaffordable No one bothered about prevention and no effort made on implementing life style interventions aggressively in real world Great talk appreciate his insight forethought with total compassion and caring He needs to be rewarded

  • @jonathanbolanos3825
    @jonathanbolanos3825 3 місяці тому

    I'm confused. He said referral to nephrology when eGFR <30, yet the guideline says transition to nephrology care when eGFR<60.

  • @abifantaw
    @abifantaw 3 місяці тому

    am internal medicine resident in ethiopia these lectures help me alot thanks

  • @ShilpaSharma-tf4of
    @ShilpaSharma-tf4of 4 місяці тому

    Very Informative. We Can also use Mutrakrichantak churan of Planet Ayurveda, its a magic herb I must say.

  • @ahmedahm1
    @ahmedahm1 6 місяців тому

    34:50 The caveat is that ACEi/ARBs are effective in persons with albuminuria +/- DM (benefit in patients without albuminuria is less consistent)

  • @GloriaAynera
    @GloriaAynera 6 місяців тому

    Thank you so much. I need to know more from this new guidelines. God bless to all kdigo group.

  • @Rene-uz3eb
    @Rene-uz3eb 7 місяців тому

    4:12 actually the graph shows less than 30% are anemic (<10 g/dl) even in stage 5, and only 5% are anemic in stage 3a 9:47 The ferritin > 500 had the highest mortality at 1.38. I just looked up the paper. Only 'iron deficiency' at < 100 ferritin had NO increase in mortality. So mortality clearly increased with the level of iron, in the presenter's paper of choice. In her defense, the paper makes the same claims even though the data is right there. I'm not sure why anyone would pick hospitalization data (for which the p value was not even significant) when you have significant mortality data. 11:08 trial results irrelevant for non-dialysis patients 15:36 find-ckd results: "The increase in hepcidin from baseline was significantly smaller with low ferritin FCM or oral iron vs high ferritin FCM at all time points up to week 52." In other words, giving a lot of iron is counterproductive since it increases hepcidin and locks down all that extra iron (aka iron overload). Hepcidin levels more than doubled even in the 'low' iron arm. That being said, 16:05 shows that Hb does respond to adding more iron alone. The question is was it worth it (not according to mortality data, and guidelines not to try to raise Hb all the way to normal), when instead Hb could have been raised with ESA alone. The trial nad no mortality data. I think the trick with excess iron raising Hb is, the targeted, way too high, ferritin levels lead to spilling of Fe iron from the ferritin into the blood, which bypasses iron release by macrophages with ferroportin, ie bypasses hepcidin regulation. That's basically freeing iron by making the liver spill over. Which over time will also end up locked into other body cells by hepcidin. 17:45 the confirm-hf trial did allow anemic patients (no limit on low Hb). So obviously they would wind up with more blood and thus more oxygen to walk a few meters more. There was no benefit to mortality. 19:28 it is not clear if high fgf23 in late ckd worsens or improves the condition 36:04 storage level of vitamin D also strongly raises HIF in hypoxia ie in anemia. So raising D storage levels should work just as well as preventing breakdown of HIF with the drug Roxadustat (note it's the circulating storage form, not the active form of vit D, that potentiates HIF): Regulation of Hypoxia Inducible Factors HIF-1 and HIF-2 by Calcidiol in Hepatocellular Carcinoma Cells Under Normoxia and Hypoxia, 2022 40:20 first time I hear a nephrologist describe lower saturation and ferritin as an improvement. According to the 'guidelines', this improvement just made the patients iron deficient.

  • @lindarosita4268
    @lindarosita4268 7 місяців тому

    Thank you for sharing , so interesting

  • @mohiesaadi8544
    @mohiesaadi8544 8 місяців тому

    Well done 👍

  • @murderthedancefloor3
    @murderthedancefloor3 9 місяців тому

    I am curious to see if these clinical guidelines align with the VA's 2019 guidelines (approved for VA physicians) in addressing patient-centered care and shared decision-making- an area where the KDIGO 2012 guidelines are lacking. Very interested to see what's ahead.

  • @ohudyansary
    @ohudyansary 10 місяців тому

    thanks a lot. how to get Kdigo 2023 guidelines?

    • @murderthedancefloor3
      @murderthedancefloor3 9 місяців тому

      Curious as well. This was uploaded in June and they say "in the coming weeks"; however, it is now October and the current guidelines are growing more and more outdated as the world has vastly changed (especially for CKD patients) since 2012.

    • @ernestflores5608
      @ernestflores5608 9 місяців тому

      Still not officially out yet, you can google KDIGO CKD Draft and can find a JULY 2023 PUBLIC REVIEW DRAFT.

  • @rebeccabins
    @rebeccabins 10 місяців тому

    Promo'SM 🤷

  • @user-qg2bg1hq8n
    @user-qg2bg1hq8n 11 місяців тому

    Great example of one person with kidney disease’s why they act to protect their health and be here for their family. Outstanding engagement.

  • @guillermodiazalonso8574
    @guillermodiazalonso8574 Рік тому

    Excelente

  • @seyifekibru4028
    @seyifekibru4028 Рік тому

    Thank you!

  • @adamualiyukukawa3748
    @adamualiyukukawa3748 Рік тому

    Words failed me on how to appreciate you for sending your Herbs to me after I place my or order which cured my Type 2 Diabetes Dr Igudia

  • @adamualiyukukawa3748
    @adamualiyukukawa3748 Рік тому

    Words failed me on how to appreciate you for sending your Herbs to me after I place my or order which cured my diabetes Dr Igudia

  • @maktaba4000
    @maktaba4000 Рік тому

    I like. Always some motivation is very important for patient to stay good for long time

  • @sravanivaka8614
    @sravanivaka8614 Рік тому

    thank you treated the patient with k 9.8 sucessfully

  • @trantuantu4906
    @trantuantu4906 Рік тому

    thank you for sharing!

  • @JimmyButler221
    @JimmyButler221 Рік тому

    From the very first I day came across Dr Igudia UA-cam channel, I knew that was going to be the end of my Type 2 diabetes. And to my surprise his herbs actually cured my Diabetes.

  • @JimmyButler221
    @JimmyButler221 Рік тому

    From the very first I day came across Dr Igudia UA-cam channel, I knew that was going to be the end of my Type 2 Diabetes. And to my surprise his herbs actually cured my Diabetes.

  • @JimmyButler221
    @JimmyButler221 Рік тому

    From the very first I day came across Dr Igudia UA-cam channel, I knew that was going to be the end of my Type 2 Diabetes. And to my surprise his herbs actually cured my Diabetes

  • @JimmyButler221
    @JimmyButler221 Рік тому

    From the very first I day came across Dr Igudia UA-cam channel, I knew that was going to be the end of my Diabetes. And to my surprise his herbs actually cured my Diabetes.

  • @FightBackAgainstDiabetes
    @FightBackAgainstDiabetes Рік тому

    *You Did Not Choose To Be Classified As Diabetic, But You Can Choose To Fight Back Against Diabetes* 💪

  • @goodmail0yahoo
    @goodmail0yahoo Рік тому

    healthy kindy longer life! healty liver color life!

  • @gojuryu3
    @gojuryu3 Рік тому

    thank you.

  • @thongxaychanvisouth432
    @thongxaychanvisouth432 Рік тому

    thank from Laos

  • @torrpaxmanorpaton5873
    @torrpaxmanorpaton5873 Рік тому

    ♥w♥o♥w♥!! Crush your competition with 'Promo sm'!!